Company Logo
Key opportunities in the oligonucleotide market include advancing therapeutics for rare and diverse diseases like neurodegenerative disorders and cancer, improving drug delivery systems, leveraging regulatory designations, and capitalizing on emerging RNA technologies to overcome existing therapy challenges.
Dublin, April 13, 2026 (GLOBE NEWSWIRE) — The “Oligonucleotides – Competitive Landscape, 2026” has been added to ResearchAndMarkets.com’s offering.
The report delves into the realm of oligonucleotides, providing extensive insights into over 280 companies and 320 drugs. It assesses therapeutics by product type, stage, administration route, and molecule type, also focusing on the inactive pipeline products. This report is a crucial resource for understanding the global landscape of oligonucleotides, a transformative class of drugs with the potential to treat a wide spectrum of genetic and acquired disorders.
Oligonucleotide therapeutics, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), face significant challenges in terms of delivery due to large molecular weight, hydrophilicity, and susceptibility to degradation, but innovations like GalNAc conjugation are enhancing delivery and specificity.
Recent therapeutic developments include:
In March 2025, Korro Bio, Inc. announced the FDA granted orphan drug designation to KRRO-110 for Alpha-1 Antitrypsin Deficiency.
In January 2025, Arrowhead Pharmaceuticals revealed the FDA’s acceptance of the NDA for plozasiran for familial chylomicronemia syndrome.
In February 2025, AusperBio reported progress on AHB-137 in clinical development for chronic Hepatitis B.
Vir Biotechnology, in December 2024, secured FDA Breakthrough Therapy designation for tobevibart and elebsiran for chronic hepatitis delta.
Stoke Therapeutics obtained breakthrough therapy designation from the FDA for STK-001 for Dravet syndrome.
The report further profiles key companies and products, offering insights into their development processes and strategic initiatives. Novartis’ LEQVIO, for instance, an siRNA-based therapeutic, has proven effective in reducing LDL-C levels. Approved by MHLW, it showcases a unique therapeutic approach in controlling cholesterol.
Astellas Pharma’s IZERVAY is another spotlight product, designed for geographic atrophy treatment, demonstrating the efficacy of RNA aptamers in reducing inflammation related to AMD.
Alnylam Pharmaceuticals continues to pioneer RNA interference with AMVUTTRA, targeting transthyretin-mediated amyloidosis and expanding treatment options for rare diseases.
The competitive landscape is further enriched by detailed company analyses covering mergers, strategic collaborations, licensing activities, and pipeline assessments. The report’s extensive evaluation includes unmet needs, upcoming therapies, and company comparisons, ensuring stakeholders have the insights needed to navigate this dynamic sector.
Industry leaders such as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Astellas Pharma continue to drive innovation, leveraging novel technologies and strategic partnerships to advance oligonucleotide therapeutics.
This report is an essential resource for understanding the evolving landscape of oligonucleotides, aiding professionals in identifying key trends and emerging opportunities in precision medicine. The in-depth commercial assessments and detailed company profiles position it as a cornerstone document for stakeholders engaged in the biotechnology and pharmaceuticals sectors.
Highlights
Key Players: Novartis, Astellas, Alnylam Pharmaceuticals, Ionis Pharmaceuticals
Key Products: LEQVIO, IZERVAY, AMVUTTRA, TEGSEDI
Companies Featured
Novartis
Astellas
Alnylam Pharmaceuticals
Ionis Pharmaceuticals
4D Molecular Therapeutics
Avidity Biosciences
Suzhou Ribo Life Science
Amgen
GSK
ProQR Therapeutics
Stoke Therapeutics
MiNA Therapeutics
Sylentis
GSK
Silexion Therapeutics
Novo Nordisk A/S
Bio-Path Holdings
Sunhawk Vision Biotech
Isarna Therapeutics
Sirnaomics
Laboratoire Thea
Dyne Therapeutics
Vertex Pharmaceuticals
Korro Bio
Praxis-Precision-Medicines
Vico Therapeutics
BioMarin Pharmaceutical
TransCode Therapeutics
TME therapeutics
ARTHEx Biotech
aptaTargets
CSPC Zhongnuo Pharmaceutical
ExoRNA Bioscience
Visirna Therapeutics
AiCuris
Comanche Biopharma
Tallac Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/yok27o
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900